Evidence Synthesis
Religare Pharmaceuticals Sees Strong Quarterly Performance with Gross Margin Accelerating to 83.05%, Up from 5.54%.
The company's revenue growth accelerated to , while its marginal operating leverage increased to . However, the stock price declined by on the day. The daily trading volume decreased to shares.
By paying you agree to our Terms and Privacy Policy.